Park Circle CO Arcus Biosciences, Inc. Transaction History

Park Circle CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	SELL	$23.23 - $30.07 $1.4 Million - $1.81 Million	-60,100 Reduced 93.91%	3,900 $102,000
Q4 2021 Feb 11, 2022	BUY	$31.38 - $48.47 $439,320 - $678,580	14,000 Added 28.0%	64,000 $2.59 Million
Q3 2021 Nov 12, 2021	SELL	$26.93 - $37.68 $1.35 Million - $1.88 Million	-50,000 Reduced 50.0%	50,000 $1.74 Million
Q2 2021 Aug 10, 2021	BUY	$22.75 - $35.77 $2.28 Million - $3.58 Million	100,000 New	100,000 $2.75 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Park Circle CO, based on Form 13F filings with the SEC.

Stay updated on Park Circle CO with notifications on news.